CTI BioPharma (CTIC) S-3 Shelf registration

EXHIBIT 12.1

STATEMENT RE: COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES

(in thousands)

	Year Ended December 31,										Nine Months Ended September 30,
	2000		2001		2002		2003		2004		2004		2005
Net loss	(51,929	)	(80,273	)	(49,903	)	(130,031	)	(252,298	)	(208,761	)	(83,811	)
Add: fixed charges	729		6,467		12,335		10,694		12,504		9,284		12,007
Earnings as defined	(51,200	)	(73,806	)	(37,568	)	(119,337	)	(239,794	)	(199,477	)	(71,804	)
Fixed charges:
Interest expensed and capitalized	544		5,988		11,240		9,326		10,988		8,148		10,842
Estimated interest component of rent	185		479		1,095		1,368		1,516		1,136		1,165
Total fixed charges	729		6,467		12,335		10,694		12,504		9,284		12,007
Ratio of earnings to fixed charges	(1	)	(1	)	(1	)	(1	)	(1	)	(1	)	(1	)

(1) Earnings (as defined) for the period were insufficient to cover fixed charges by an amount equal to the net loss for the period.